Omeprazole and the proton pump inhibitors explained

Proton pump inhibitors (PPIs) are among the most widely used medicines globally for reducing stomach acid. The generic names of these medicines share the stem "-prazole", making them easily identifiable. Omeprazole, the first of this class, was a significant development in gastroenterology when it was introduced in the late 1980s. Today, the class includes several other established medicines, such as pantoprazole, lansoprazole, and esomeprazole. They are used to treat a range of conditions caused by excess acid, though they have also become a subject of public health focus due to their widespread availability and long-term use.

How the "-prazole" class works

The stomach lining contains specialized cells responsible for secreting the acid needed for digestion. These cells rely on an enzyme called the hydrogen/potassium ATPase, commonly referred to as the "proton pump". Proton pump inhibitors work by binding to these pumps and deactivating them. By blocking the final step of acid production, PPIs provide a profound and long-lasting reduction in gastric acidity compared to older classes of acid-reducing drugs, such as H2-receptor antagonists.

These medicines are generally indicated for conditions where reducing stomach acid allows tissue to heal or prevents further damage. Common indications include gastro-oesophageal reflux disease (GORD), erosive oesophagitis, and stomach and duodenal ulcers. They are also frequently used alongside antibiotics in regimens designed to eradicate *Helicobacter pylori*, a bacterium strongly associated with peptic ulcers. Because they take time to accumulate in the system and act on actively secreting pumps, PPIs are generally more effective at preventing heartburn than providing immediate relief for an active attack.

The global Rx-to-OTC switch

When omeprazole was first brought to market, it was available exclusively by prescription, reflecting the need for proper medical diagnosis of underlying gastrointestinal conditions. However, as years of post-marketing surveillance demonstrated a strong safety profile for short-term use, regulatory authorities began approving lower-strength versions for over-the-counter (OTC) sale. This Rx-to-OTC switch is a regulatory process that allows adults to purchase the medicine directly from a pharmacy for short-term relief of occasional heartburn or acid indigestion, without requiring a doctor's consultation.

In 2003, the United States Food and Drug Administration (FDA) approved the first OTC proton pump inhibitor. Similar regulatory transitions have occurred in many countries, including across Europe and South Africa. In South Africa, the scheduling of medicines is managed by SAHPRA, and certain lower-dose PPIs have been down-scheduled to allow pharmacy-level dispensing. This shift has significantly changed how the public accesses these medicines, promoting self-care for minor, self-recognised ailments while reserving higher strengths and longer durations for prescription use.

The generic PPI market

The original branded PPIs—such as Losec (omeprazole) and Nexium (esomeprazole)—were major commercial successes during their patent-protected years. As the patents for these molecules expired, the market opened to generic manufacturers. Because the chemical synthesis of these molecules is well-documented, a large number of generic companies now produce omeprazole and pantoprazole, creating a highly competitive global market.

This extensive generic competition has driven down the cost of treatment considerably. To be approved, generic PPIs must demonstrate bioequivalence to the original branded product, meaning they deliver the same amount of active ingredient into the bloodstream at the same rate. In South Africa, the pricing of these medicines is regulated under the Single Exit Price framework, which sets a maximum price that can be charged. Patients and healthcare providers can use HealthSA to search for registered PPIs by their active ingredient names and compare their regulated prices.

Pharmacovigilance and long-term considerations

The sheer volume of PPI use worldwide means that even rare adverse events can affect a significant number of people. Consequently, these medicines are subject to ongoing pharmacovigilance monitoring by health authorities. While they are generally considered safe for short-term use, there has been growing regulatory and scientific focus on the risks associated with long-term, continuous use.

Observational studies have suggested associations between prolonged PPI use and an increased risk of kidney issues, bone fractures, and certain nutrient absorption problems, such as low magnesium or vitamin B12 levels. Regulators note that establishing causation can be complex, as patients on long-term PPIs often have other underlying health conditions. Nevertheless, regulatory agencies generally recommend that PPIs be used at the lowest effective dose for the shortest necessary duration to manage the condition. Both the European Medicines Agency (EMA) and other national regulators periodically review this data to update prescribing information and ensure the benefits of the "-prazole" class continue to outweigh any potential risks.